BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.90% | 12.87% | 12.39% | 18.36% | 19.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.90% | 12.87% | 12.39% | 18.36% | 19.36% |
| Cost of Revenue | 21.12% | 14.52% | 8.73% | -0.25% | 0.45% |
| Gross Profit | 0.97% | 11.44% | 15.98% | 37.37% | 40.41% |
| SG&A Expenses | 8.65% | 2.18% | -2.85% | -0.59% | 9.03% |
| Depreciation & Amortization | -43.73% | -55.18% | -50.47% | -59.08% | -44.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.89% | 8.02% | 2.73% | -1.89% | 2.68% |
| Operating Income | -8.85% | 37.22% | 80.98% | 202.31% | 207.01% |
| Income Before Tax | -42.82% | -10.94% | 73.53% | 181.25% | 184.09% |
| Income Tax Expenses | -22.32% | 16.25% | 129.69% | 334.30% | 371.57% |
| Earnings from Continuing Operations | -48.70% | -18.26% | 61.47% | 156.15% | 154.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.70% | -18.26% | 61.47% | 156.15% | 154.99% |
| EBIT | -8.85% | 37.22% | 80.98% | 202.31% | 207.01% |
| EBITDA | -11.18% | 26.68% | 58.77% | 136.68% | 131.42% |
| EPS Basic | -49.09% | -18.80% | 60.21% | 153.60% | 152.09% |
| Normalized Basic EPS | -6.55% | 35.01% | 76.73% | 188.16% | 193.13% |
| EPS Diluted | -49.32% | -19.41% | 62.06% | 158.27% | 156.37% |
| Normalized Diluted EPS | -5.02% | 37.88% | 79.51% | 192.87% | 194.09% |
| Average Basic Shares Outstanding | 0.85% | 0.93% | 1.02% | 1.10% | 1.15% |
| Average Diluted Shares Outstanding | -1.48% | -1.98% | -0.83% | 0.58% | 1.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |